Neogenix Oncology, Inc. announced today that members of its scientific staff will present laboratory studies of NEO-101, a novel monoclonal antibody in development to diagnose and treat pancreatic and colorectal cancers. The presentation is scheduled at the American Association of Cancer Research (AACR) 102nd Annual Meeting being held April 1-6, 2011 at the Orange County Convention Center, Orlando, FL, USA.
“Neogenix is committed to building our preclinical knowledge base, of both NEO-101 and its target molecule, which is critical to understanding the pathology biology behind these cancers”
NEO-101 (NPC-1C, or Ensituximab) is a chimeric monoclonal antibody being developed as a novel biological treatment for pancreatic and colorectal cancer and is currently in Phase I clinical trials at The Johns Hopkins University Hospital, Duke University Medical Center and North Shore University/Long Island Jewish Medical Center. NEO-101 is the first in the Neogenix pipeline of antibodies intended to target specific cancers. The NEO-101 target appears to be a variant of MUC5AC that is expressed specifically by human colon and pancreatic tumor tissues and cell lines that in testing to date, have only occasionally shown, minimal and weak cross-reactivity to certain normal GI tract tissues. The preclinical data to be presented includes in vitro mechanism of action, immunofluorescent cell staining, in vivo anti-tumor efficacy, bio-distribution, and toxicokinetic studies.
"Neogenix is committed to building our preclinical knowledge base, of both NEO-101 and its target molecule, which is critical to understanding the pathology biology behind these cancers," said Neogenix Chief Executive Officer, Philip M. Arlen, MD.
Poster Presentation Information:
Abstract Title: Pre-clinical studies of a novel antibody to treat pancreatic and colorectal cancers
Poster Session Date/Time: Immunology 6; Tuesday April 5th at 1:00pm-5:00pm.
Permanent Abstract ID: 4584
Location: Exhibit Hall A4-C; Poster Session 31; Poster #26
USC Norris to open state-of-the-art cancer center in Newport Beach with advanced radiation therapy